Last $117.53 USD
Change Today -0.11 / -0.09%
Volume 637.3K
BDX On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 4:15 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

becton dickinson and co (BDX) Snapshot

Open
$117.97
Previous Close
$117.64
Day High
$118.09
Day Low
$117.26
52 Week High
06/9/14 - $120.66
52 Week Low
09/3/13 - $96.73
Market Cap
22.5B
Average Volume 10 Days
590.0K
EPS TTM
$6.07
Shares Outstanding
191.8M
EX-Date
09/5/14
P/E TM
19.4x
Dividend
$2.18
Dividend Yield
1.81%
Current Stock Chart for BECTON DICKINSON AND CO (BDX)

becton dickinson and co (BDX) Related Businessweek News

View More BusinessWeek News

becton dickinson and co (BDX) Details

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company’s BD Medical segment produces medical devices that are used in various healthcare settings. This segment’s products include needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles used in the treatment of diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; and generic prefilled injectables. Its BD Diagnostics segment provides products for the collection and transport of diagnostics specimens; and instrument systems and reagents to detect various infectious diseases, healthcare-associated infections, and cancers. This segment’s products comprise integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing systems; molecular testing systems; microorganism identification and drug susceptibility systems; liquid-based cytology systems; rapid diagnostic assays; microbiology laboratory automation; and plated media. The company’s BD Biosciences segment offers research and clinical tools that facilitate the study of cells and their components. This segment’s products include fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; cell imaging systems; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

29,979 Employees
Last Reported Date: 11/27/13
Founded in 1897

becton dickinson and co (BDX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $930.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $144.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $690.0K
Executive Vice President
Total Annual Compensation: $605.7K
Senior Vice President and General Counsel
Total Annual Compensation: $516.3K
Compensation as of Fiscal Year 2013.

becton dickinson and co (BDX) Key Developments

Becton, Dickinson and Company launches BD Autoshield Duo Pen Needle

BD Medical, a segment of Becton, Dickinson and Company announced the retail pharmacy launch of BD AutoShield Duo, the only pen needle with patented dual front and back-end shields that provides greater convenience and safety before and after injecting. The technology conceals the needle, helping to alleviate pre-injection anxiety while helping to reduce the risk of accidental needle stick for patients who inject insulin or other diabetes drugs. The BD AutoShield Duo pen needle is easier to use because there is no inner needle shield to manage and no re-capping necessary, allowing people to dispose of the pen needle in a sharps container when it's convenient to help avoid risk of an accidental needle stick. A front shield automatically covers the needle before and after an injection, and a second shield passively covers the back end needle after injection. Additionally, the front shield helps conceal the needle to reduce injection-related anxiety. In addition to helping reduce the risk of accidental needle sticks, BD AutoShield Duo pen needles include audible and visual cues for a more confident injection experience. The front shield clicks to indicate that the needle has fully penetrated the skin and a red band appears when the injection is completed, while the back end shield covers the rear needle point when the pen needle is removed from the pen. BD AutoShield Duo pen needles support the current American Association of Diabetes Educators practice advisory for injection technique guidelines calling for the use of shorter needles, proper site rotation, and using needles only one time (single use). BD announced the retail pharmacy launch of the BD AutoShield Duo pen needle on August 6, 2014 at the American Association of Diabetes Educators Annual Meeting in Orlando, Florida. The product is now available nationwide at major retailers and distributors.

Becton, Dickinson and Company Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2014; Reaffirms Earnings Guidance for the Full Year of 2014

Becton, Dickinson and Company announced unaudited consolidated earnings results for the third quarter and nine months ended June 30, 2014. For the quarter, the company reported revenues of $2,157 million compared to $2,053 million a year ago. Operating income was $445 million compared to $405 million a year ago. Income from continuing operations before income taxes was $423 million compared to $379 million a year ago. Income from continuing operations was $326 million or $1.65 per diluted share compared to $292 million or $1.47 per diluted share a year ago. Net income was $326 million or $1.65 per diluted share compared to $302 million or $1.52 per diluted share a year ago. Adjusted diluted EPS from continuing operations was $1.68 compared to $1.54 a yea ago. For the nine months, the company reported revenues of $6,244 million compared to $5,953 million a year ago. Operating income was $1,204 million compared to $1,178 million a year ago. Income from continuing operations before income taxes was $1,145 million compared to $1,105 million a year ago. Income from continuing operations was $884 million or $4.47 per diluted share compared to $838 million or $4.21 per diluted share a year ago. Net income was $884 million or $4.47 per diluted share compared to $1,203 million or $6.04 per diluted share a year ago. Adjusted diluted EPS from continuing operations was $4.57 compared to $4.28 a yea ago. The company reaffirms its previously communicated currency-neutral revenue guidance range of 4.5 to 5.0%. On a reported basis, the company expects revenue growth of 4.0 to 4.5%. The company is also reaffirming its previous guidance for diluted earnings per share from continuing operations for the full fiscal year to be between $6.22 and $6.25 excluding the impact of the previously aforementioned adjustments. On a reported basis, earnings per share for the full fiscal year 2014 are expected to be between $6.12 and $6.15. This represents growth of 7.0 to 7.5% over 2013 adjusted diluted earnings per share of $5.81. On a foreign currency-neutral basis, adjusted diluted earnings per share growth is expected to be between 10.0 to 10.5%, or 11.0 to 11.5% excluding the incremental impact of the medical device tax. The company is reducing gross profit guidance to between 51.2% to 51.4%. This is largely due to the cost to remediate quality issues, including an incremental investment in manufacturing processes within the Pharmaceutical Systems business that impacts the second half of the year.

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2014

The Board of Directors of BD (Becton, Dickinson and Company) declared a quarterly dividend of 54.5 cents per common share payable on September 30, 2014 to holders of record on September 9, 2014. The indicated annual dividend rate is $2.18 per share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BDX:US $117.53 USD -0.11

BDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $57.99 USD -0.34
Boston Scientific Corp $12.66 USD +0.06
Smith & Nephew PLC 1,064 GBp +17.00
Stryker Corp $82.90 USD +1.01
Zimmer Holdings Inc $100.62 USD +0.81
View Industry Companies
 

Industry Analysis

BDX

Industry Average

Valuation BDX Industry Range
Price/Earnings 23.9x
Price/Sales 2.7x
Price/Book 4.2x
Price/Cash Flow 23.2x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BECTON DICKINSON AND CO, please visit www.bd.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.